Long-term sutimlimab improves quality of life for patients with cold agglutinin disease: CARDINAL 2-year follow-up

Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia with a substantial burden on patient’s quality of life. CARDINAL was a 2-part, open-label, single-arm, multicenter phase 3 study evaluating the C1s inhibitor, sutimlimab, for treatment of CAD. Part A consisted of the pivotal...

Descripción completa

Detalles Bibliográficos
Autores principales: Röth, Alexander, Broome, Catherine M., Barcellini, Wilma, Tvedt, Tor Henrik Anderson, Miyakawa, Yoshitaka, D’Sa, Shirley, Cella, David, Bozzi, Sylvie, Jayawardene, Deepthi, Yoo, Ronnie, Shafer, Frank, Wardęcki, Marek, Weitz, Ilene C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558612/
https://www.ncbi.nlm.nih.gov/pubmed/37459203
http://dx.doi.org/10.1182/bloodadvances.2022009318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558612/
https://www.ncbi.nlm.nih.gov/pubmed/37459203
http://dx.doi.org/10.1182/bloodadvances.2022009318

Ejemplares similares